New lung cancer strategy aims to cut chemo side effects while keeping efficacy
NCT ID NCT07241819
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests a drug called ivonescimab, given alone or with chemotherapy, before and after surgery for people with a certain type of lung cancer (non-small cell lung cancer) that can be removed. The goal is to see if using less chemotherapy based on a patient's PD-L1 level can reduce side effects while still being effective. About 66 adults aged 18-75 with stage II-IIIB cancer will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for II-IIIB (T3N2) RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.